Biophan CEO Michael Weiner to Present Advanced Biomedical Solutions and Business Plan at NanoEquity Europe Conference 2005, June 13-14; CEO to Discuss Strategy to Commercialize Company's Proprietary Nanotechnologies
Biophan CEO Michael Weiner will make the presentation, entitled, "Converting Nanotechnologies into Shareholder Value." His presentation is designed to highlight the Company's range of innovative nanotechnology solutions, patent portfolio, and proprietary technologies. "Many of Biophan's institutional and individual shareholders are based in Germany," Mr. Weiner said. "I am looking forward to updating them on our progress at this important international nanotechnology conference. The Frankfurt Stock Exchange has been an important contributor to our overall trading volume and growing shareholder base. We are very pleased to be invited back again this year." Mr. Weiner's presentation is scheduled for 11:10 am, Tuesday, June 14, in the Liberty II room.
“Many of Biophan's institutional and individual shareholders are based in Germany”
Biophan's intellectual property portfolio contains 127 U.S. issued, pending, and exclusively licensed patents, in addition to 46 international issued and pending patents. Biophan is developing a range of next-generation nanotechnology-based solutions, including technologies to make implanted biomedical devices and surgical instruments safe and image compatible for use in Magnetic Resonance Imaging (MRI) environments. Biophan will present its nanotechnology applications for controlling drug release from coated surfaces, and for limiting the toxic effects of powerful drugs. An update on the progress of its biothermal battery, powered by body heat, will also be included in the presentation, as will images of its MRI imageable stents and vena cava filters.
For more information about the First NanoEquity Europe Conference 2005, please visit http://www.deutsche-boerse.com.
About NanoEquity Europe Conference 2005
The NanoEquity Europe Conference is sponsored by Deutsche Borse Group, owner of Frankfurt Stock Exchange, Europe's largest stock exchange. Its goal is to create a greater long-term awareness on the domestic and international capital markets for companies from the sectors high-tech engineering - with this particular event focusing on nano- and micro technologies. The conference aims to present issues related to the capital market and the acquisition of equity for companies from all areas of nano- and micro technology. It will bring together academic experts and decision makers from companies and the capital markets. The conference will be held in German and English.
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 127 U.S. patents, licenses, or applications. This total includes 37 issued U.S. patents, 8 recently-allowed applications that will issue as patents in the near future, and 82 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.